U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.